B-
Overall grade
B
Financial quality
The sleeper story is DOCS just launched their Google moment - targeting pharma's $19B paid search market versus their current $2.5B TAM - but they're deliberately throttling monetization in their 'AI investment year.' Revenue growth crashed from 10% to 5% while AI usage exploded 30% YoY, creating a massive engagement-monetization gap they plan to close in the back half. The binding constraint isn't demand (140 health systems bought AI, nearly half of users adopted it) but their physician-first obsession delaying commercial launches for regulatory review. 'We paid $63 million for Pathway AI last summer, and now we're spending against the opportunity it unlocked' captures their all-in bet on multi-billion TAM expansion. My view changes if AI Search revenue doesn't materially ramp in Q1-Q2 FY27 or if gross margins fall below 85% without revenue acceleration.
The 30-second version
- AI search is their Google moment but they're deliberately throttling monetization
- Free cash flow hit first-ever 9-figure quarter while growth decelerated to 5% YoY
- Gross margins getting crushed by AI compute costs with no revenue offset yet
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Revenue | $185M (+10% YoY) | $145M (+5% YoY) |
| Full Year Revenue | $571M (+13% guide) | $645M (+13% YoY) |
| Adjusted EBITDA Margin | 60% | 45% |
| Full Year EBITDA Margin | 55% | 55% |
| Free Cash Flow | $58.5M | $107M |
| Full Year FCF | $267M | $317M (+19% YoY) |
| Non-GAAP Gross Margin | 91% | 89% |
| Net Revenue Retention | 112% | 109% |
Accountability tracked
8 new promises made4 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →